Phibro Animal Health (PAHC) earnings history
Most recent quarter
- Fiscal period
- Q4 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.85
- EPS estimate
- $0.71
- EPS surprise
- +19.25%
- Revenue surprise
- +4.07%
- Revenue
- $396.7M
- Revenue estimate
- $381.2M
- Reported
- Aug 26, 2026
Phibro Animal Health reported fiscal Q4 2026 results on August 26, 2026. Earnings per share were $0.85, ahead of the $0.71 estimate by 19.25%. Revenue of $396.7 million beat the $381.2 million consensus by 4.07%. Compared with fiscal Q4 2025, EPS rose about 49% from $0.57 and revenue rose about 5% from $378.7 million.
Fiscal 2026 was the strongest year in the table. Annual EPS reached $3.21, up about 54% from $2.09 in fiscal 2025, which itself was up about 76% from $1.19 in fiscal 2024. Fiscal 2022 to 2024 held between $1.19 and $1.31. Revenue rose from $1.02 billion in fiscal 2024 to $1.30 billion in fiscal 2025 and $1.52 billion in fiscal 2026. Q4 2026 revenue was the highest quarter here, and Q2 2026 EPS of $0.87 the highest per-share figure. Phibro beat the EPS estimate in each of the last eight quarters and in 14 of the last 20.
Fiscal Q1 results came between November 2 and November 9 in each of the past five years. That points to early November 2026 for the next report, the first of fiscal 2027. It will show whether the year-over-year growth of fiscal 2026 carries into the new year.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q4 2026 | Aug 26, 2026 | $0.71 | $0.85 | +19.25% | $396.7M | SEC |
| Q3 2026 | May 6, 2026 | $0.71 | $0.76 | +6.59% | $383.5M | SEC |
| Q2 2026 | Feb 4, 2026 | $0.67 | $0.87 | +29.85% | $373.9M | SEC |
| Q1 2026 | Nov 5, 2025 | $0.62 | $0.73 | +17.27% | $363.9M | SEC |
| Q4 2025 | Aug 27, 2025 | $0.52 | $0.57 | +9.34% | $378.7M | SEC |
| Q3 2025 | May 7, 2025 | $0.52 | $0.63 | +21.04% | $347.8M | SEC |
| Q2 2025 | Feb 5, 2025 | $0.43 | $0.54 | +27.06% | $309.3M | SEC |
| Q1 2025 | Nov 6, 2024 | $0.25 | $0.35 | +41.13% | $260.4M | SEC |
| Q4 2024 | Aug 28, 2024 | $0.33 | $0.41 | +23.01% | $273.2M | SEC |
| Q3 2024 | May 8, 2024 | $0.29 | $0.31 | +6.90% | $263.2M | SEC |
| Q2 2024 | Feb 7, 2024 | $0.28 | $0.33 | +17.86% | $249.9M | SEC |
| Q1 2024 | Nov 8, 2023 | $0.23 | $0.14 | −39.13% | $231.3M | SEC |
| Q4 2023 | Aug 30, 2023 | $0.37 | $0.38 | +2.01% | $255.0M | SEC |
| Q3 2023 | May 3, 2023 | $0.34 | $0.29 | −13.43% | $245.7M | SEC |
| Q2 2023 | Feb 8, 2023 | $0.30 | $0.34 | +12.40% | $244.6M | SEC |
| Q1 2023 | Nov 9, 2022 | $0.26 | $0.21 | −20.24% | $232.5M | SEC |
| Q4 2022 | Aug 24, 2022 | $0.38 | $0.36 | −4.43% | $255.3M | SEC |
| Q3 2022 | May 4, 2022 | $0.35 | $0.33 | −6.59% | $239.6M | — |
| Q2 2022 | Feb 9, 2022 | $0.33 | $0.37 | +12.91% | $232.7M | — |
| Q1 2022 | Nov 2, 2021 | $0.29 | $0.25 | −14.76% | $214.7M | — |
Quarterly revenue
Frequently asked questions
When did Phibro Animal Health (PAHC) last report earnings?
Phibro Animal Health last reported on Aug 26, 2026, covering fiscal Q4 2026.
Did PAHC beat earnings estimates?
Yes. Phibro Animal Health reported EPS of $0.85 for Q4 2026 against a $0.71 estimate — a 19.25% beat.
How much revenue did PAHC report last quarter?
Phibro Animal Health reported $396.7M in revenue for Q4 2026, against a consensus estimate of $381.2M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.